Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$2.0 - $4.4 $68,444 - $150,576
-34,222 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$1.61 - $3.62 $55,097 - $123,883
34,222 New
34,222 $64,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $424M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Piper Sandler & Co. Portfolio

Follow Piper Sandler & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Piper Sandler & Co., based on Form 13F filings with the SEC.

News

Stay updated on Piper Sandler & Co. with notifications on news.